Study Design. Cost-effectiveness analysis alongside a cluster randomized controlled trial. Objective. To study the cost-effectiveness of 2 low back pain guideline implementation (GI) strategies. Summary of Background Data. Several evidence-based guidelines on management of low back pain have been published. However, there is still no consensus on the effective implementation strategy. Especially studies on the economic impact of different implementation strategies are lacking. Methods. This analysis was performed alongside a cluster randomized controlled trial on the effectiveness of 2 GI strategies (physician education alone [GI] or physician education in combination with motivational counseling [MC] by practice nurses)--both compared with the postal dissemination of the guideline (control group, C). Sociodemographic data, pain characteristics, and cost data were collected by interview at baseline and after 6 and 12 months. L ow Back Pain (LBP) is one of the most prominent problems in the industrialized countries. Epidemiological studies report lifetime prevalences of 70% to 90%. 1 , 2 Although most patients recover spontaneously, there is a high rate of recurrences (70%) and 7% to 10% of patients develop chronic LBP, which leads to high health care cost due to sick leave and early retirement. Facing the problem of the characteristic diversity of providers and possible treatment options, current research activities focus on the implementation of evidence-based care for patients with LBP. Although guideline implementation (GI) strategies have been studied with respect to provider adherence and patient outcomes, 4 -6 it is still unsure whether these activities actually alter subsequent health care cost. Evidence from economic evaluations is lacking despite the importance of such studies for decision and policy makers when deciding on the most effi cient resource use.
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The aim of our study was to perform a cost-effectiveness analysis on 2 LBP GI strategies that have been tested in a cluster randomized controlled trial in German general practices.
At the index visit, patients were asked to fi ll out 2 sets of questionnaires, one while waiting and another one at home (sociodemographic and disease-related data, for postal return in a prepaid envelope). One baseline telephone interview (within 4 weeks) and 2 follow-up interviews (after 6 and 12 months) were performed by specially trained study nurses. Data on LBP-related health care resource use were collected during all 3 interviews. To shorten interviews, we had to omit non-medical costs such as travel and time expenses or out-ofpocket costs.
Interventions
Practices were assigned to the 3 study arms by permuted block randomization. General practitioners (GPs) in both intervention groups (GI and GI plus motivational counseling [MC] ) were trained in using the LBP guideline of the German College of General Practitioners and Family Physicians (DEGAM) 8 : The guideline consists of 4 modules: a detailed version and a pocket card for physicians, a prescription-like short form information, and a more detailed information fl yer for patients. Three interactive seminars for participating GPs were held, including information on performance of the diagnostic triage and identifi cation of red fl ags (fi rst session), early identifi cation of yellow fl ags, including general behavioral principles on management of chronic pain patients (second session), and informing and advising patients (third session). The third session gave room for discussion of implementation barriers and individual experiences. All doctors of the intervention groups received information about relevant local facilities for pain patients (self-help groups, fi tness clubs, teaching sessions organized by health insurers, specialists, etc .). Individual educational visits by study nurses to participating GPs were done twice to hand over the guideline and, after 3 to 6 months, to discuss individual problems with GI.
During the third educational session, GPs of the GI plus MC group were introduced to MC strategies. Two nurses per practice received a 20-hour training (2 full-day workshops and 1-3 supervision sessions) designed to increase the nurses' skills to motivate LBP patients for regular physical activity. Practice nurses were asked to invite all identifi ed patients for up to 3 counseling sessions (maximum 10-15 minutes each), the fi rst session within 1 to 3 weeks after inclusion in the study. They were encouraged to use specifi cally designed brochures on motivational and behavior change and posters to communicate the key messages. Study coordinators contacted the practice nurses regularly to identify barriers and problems with regard to the implementation of this new counseling strategy.
The control group received the guideline via postal mail, which has been proven to be ineffective with respect to patient outcomes. 9 
Study Sample
All patients consulting for LBP were recruited consecutively. Inclusion criteria were LBP on the day of inclusion, aged 20 years and older, ability to read and to understand German, and written consent. Exclusion criteria were pregnancy and isolated thoracic or cervical pain.
Setting
The study was conducted in 2 German regions (Marburg and Göettingen) in 2003 to 2004. Overall, 126 GPs (73 men, mean age of 49 years) belonging to 118 practices (57 group practices and 69 single practices) participated.
Clinical Measures
For description of pain, we asked for the pain intensity (numeric analogue scale), days in pain during the previous year, and a possible radiation of pain. For classifi cation of the natural history of LBP, we used the von Korff scale to grade the severity of chronic pain.
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Effect Measures
The main outcome to assess the implementation effectiveness was functional capacity measured with the 12-item Hannover Functional Ability Questionnaire for Measuring Back PainRelated Functional Limitations at baseline (questionnaire) and after a 6-and 12-month period (interview).
11 , 12 Normal function shows scores of 80% to 100%; scores around 70% equal a moderately limited function and scores below 60% show a severely limited function.
Secondary outcomes were physical activity during 1 week prior to the interview, days in pain and days of sick leave referring to the 6-month period prior to the 2 follow-up interviews, and quality of life measured with the EuroQol 13 after a 12-month period providing us with a single index value on a visual analogue scale (0-100).
Sociodemographic characteristics were assessed for description of the study sample. Furthermore, GPs reported for each patient the presence of complicating factors (generally unwell, neurological defi cits, history of cancer, chronic infl ammatory disease, osteoporosis with danger of fracture, immune defi ciency, or severe trauma).
Measurement of Health Care Utilization
Consultation of health care providers (GP, specialists), diagnostic and therapeutic procedures, and auxiliaries were given in types and numbers. For pharmaceuticals, information given by patients was initially translated into drug codes. However, for practical reasons we had to change to free-text answers on type, doses, and package size of the medication during follow-up. Data on hospital and rehabilitation were given in days of care and reason for admission ( e.g. , surgery, pain management).
Because we had no data on insurance status, we postulated a 10% rate of privately insured patients for all direct cost categories as this percentage corresponds to the average of privately insured patients in Germany. Physician consultations and diagnostic or therapeutic procedures were priced using providerspecifi c charges. The costs for drugs were based on package prices according to the offi cial German price list of drugs. Expenditure for hospital care is based on diagnosis-related groups or on department-specifi c daily charges. Inpatient rehabilitation was valued by sector-specifi c charges, all data infl ated for 2004 by the sector-and state-specifi c infl ation rate. If necessary, we accounted for patient copayment in all cost categories. Cost estimations for auxiliaries are based on average prices (recommended by Krauth et al 14 ; infl ated for 2004) or by personal information from medical supply stores.
For an estimation of indirect costs, we used the human capital approach multiplying the number of missed work hours with the average daily labor cost in Germany. 15 A more detailed description of valuation in costs as well as sources of information may be seen in Becker et al . 16 GI costs were calculated from the study perspective as well as from a societal perspective ( Table 1 ) . Costs for guideline development were not accounted for because they refer to all 3 study arms.
Statistical Analysis
Basic statistical analysis was performed with SPSS 17.0 (SPSS, Inc., Chicago, IL) and R (R Development Core Team, http://www.R-project.org/) . 17 Our sample size calculation was based on changes in the primary outcome functional capacity: Expecting small effects ( f = 0.1) and a dropout rate of 25%, we aimed for 1874 patients ( α = 0.05, power 1 − β = 80%, intracluster correlation ρ = 0.03, expected cluster size n = 16).
Nonparametric bootstrapping using the program R (with 100,000 simulated replicates) was applied to present means and confi dence intervals (CIs) of cost data for each study group. Incremental cost-effectiveness ratios are based on the differences in total costs between the intervention groups and the control group divided by the difference in effects for functional capacity, days in pain, or quality of life. They are (BUGS project, http://www.mrc-bsu.cam.ac.uk/bugs/welcome.shtml) calculated with bootstrapping (5000 simulated replicates) and presented on a cost-effectiveness plane. Acceptability curves were drawn to show the statistical confi dence of costeffectiveness as a function of willingness to pay, measured in Euro (€) per point on the effectiveness scale.
For sensitivity analysis, we performed Markov-chain Monte Carlo simulations with the WinBUGS software 18 to adjust for direct and indirect costs during the 6 months prior to recruitment as well as for clustering of data. This was done using a Bayesian hierarchical model developed by Grieve et al 19 that jointly models a cost and an effectiveness variable as well as their correlation and includes practice clusters by means of a random effect. According to Nixon and Thompson, 20 we further extended this model to take into account costs during the 6 months prior to recruitment as a covariable for both effectiveness and cost. The effectiveness variable, that is, functional capacity, was assumed to be normally distributed. To account for the skewness of cost (here, during the period after recruitment), the model involved a gamma distribution for this variable. Three Markov chains were generated (in total 3 × 6667, that is, 20,001 replicates that were actually analyzed). Two-dimensional confi dence ellipses were derived from the joint distribution of the cost and functional capacity for the replicates.
RESULTS
We fi nally included 1378 patients from 76 practices (1-20 per practice) in the main study (participation rate: 44%, dropout: 12.1% in 12 months). Reasons for exclusion from the main study are given in Figure 1 . For cost analysis, we had to further exclude 55 patients who refused to participate in the baseline interview on health care utilization and 1 patient who showed implausible data on days of sick leave. This left us with 1322 eligible patients for the cost-effectiveness analysis. Baseline and sociodemographic characteristics stratifi ed for study groups are shown in Table 2 and Table 3 and in more detail in Becker et al . 7 , 16 Absence From Work and Health Care Costs After 6-month follow-up, 93 patients of the GI group (mean: 23 days; 95% CI, 16-32; median: 10 days) and 90 patients of the GI plus MC group (mean: 25 days; 95% CI, 16-33; median: 12 days) reported absence from work because of LBP during the previous 6-month period. Less patients (n = 81) in the control group showed on average more days off work (mean: 40 days; 95% CI, 29-52; median: 14 days) than those in the intervention groups. At 12-month followup, 62 patients of the GI group (mean: 19 days; 95% CI, 11-28; median: 10 days), 51 patients of the GI plus MC group (mean: 22 days; 95% CI, 12-31; median: 10 days), and 53 controls (mean: 29 days; 95% CI, 16-42; median: 10 days) reported absence from work again during the previous 6-month period. Table 4 shows differences in means of health care costs between pairs of the 3 study groups during follow-up. Results are shown for months 1 to 6 and 7 to 12 after recruitment. Direct, indirect, and total costs during follow-up are markedly lower in both intervention arms compared with controls. However, this difference was already present at baseline ( Table 5 ) and has been accounted for in additional sensitivity analyses. Table 6 presents the results that contribute to the calculation of cost-effectiveness ratios for both intervention groups compared with controls. With respect to intervention effects after 6 and 12 months, improvement of functional capacity was more pronounced (but not signifi cant) in the intervention groups compared with controls. Tendencies in effect remain visible after 12 months. There are no signifi cant effects regarding the other secondary outcomes: physical activity or quality of life. lower costs and better functional capacity for GI versus C (95% for GI plus MC vs. C). The acceptability curves show a maximum statistical confi dence of 0.98 for a willingness to pay of 115€ per point on the functional capacity scale (GI plus MC vs. C: 0.998 for 134€). At 12-month follow-up, trends are still visible for all comparisons but less prominent. The maximum confi dence of 0.97 for the intervention (GI group vs. controls) being
Intervention Effects
Cost-Effectiveness
Taking into account the health care costs during follow-up (months 1-6) both interventions seem less expensive and more effective than the control group concerning the primary outcome functional capacity as well as for days in pain. Figures 2 and 3 show the cost-effectiveness plane for functional capacity comparing GI or GI plus MC with the control group (C). Most bootstrap ratios (84%) appear in the bottom right quadrant meaning seems slightly more cost-effective in most outcomes than physician education alone. However, any differences in cost-effectiveness diminish when adjusting for clustering of data and costs during a 6-month period prior to patient recruitment.
Limitations
Our results are based on a secondary analysis of a randomized controlled trial and therefore have to be interpreted with caution. With respect to external validity, we have to consider selection bias caused by physicians participating in research studies and by study patients who are more likely to follow an activity-enhancing therapy approach. However, a possible Figure 4 shows the results on incremental functional capacity at 6-month follow-up without adjustment for clustering (solid circles), taking into account cluster randomization (dotted circles), as well as allowing for baseline differences in costs in addition to clustering (dashed circles). There still remains a superior effect in functional capacity but no reduction in costs.
Sensitivity Analysis
DISCUSSION
In this cost-effectiveness analysis, patients in both intervention groups showed lower costs compared with controls at 6-and 12-month follow-up. MC in addition to physician education We decided to perform a sensitivity analysis with respect to differences in costs prior to the beginning of the study in order to adjust for health care utilization bias. Possibly, these differences are caused by some sort of selection bias as by imbalances of patient comorbidities. We cannot comment on these, but we found no differences in quality of life which may serve as a surrogate for general health status.
Bias due to insuffi cient blinding is also conceivable. The baseline data collection took place after randomization on practice level. Patients could have noticed which study groups they were in and answered the questions accordingly. However, this would be the same concerning data on health care utilization as well as for data on depression, activity, and selfeffi cacy, in which we found no baseline imbalances. Possibly due to the skewed distribution in health care utilization data and costs, such that few patients account for the majority of total expenses, imbalances are much more likely to occur for costs than in different outcomes. This would mean that higher sample sizes than ours are needed to achieve equal distributions in health care utilization and costs, even in a randomized setting. Whether health care utilization prior to the study should be considered at all is up for discussion, especially when there are no imbalances in clinical parameters such as back pain severity. This has not been recommended in current recommendations on cost-effectiveness studies on overestimation of cost differences between intervention groups and controls will be attenuated, because the control physicians and patients are also likely to be more enthusiastic about participating in a GI trial than a comparable population sample.
Cost data in our study are gained by retrospective interviews. We cannot exclude recall bias, information bias ( e.g. , by patients who are unable to distinguish between LBPrelated procedures and others), or social desirability bias. Under-or overestimation of costs is possible. However, these refer to all study groups and rather affect the generalizability of the study results than any group differences. Total costs are most likely underestimated, because we had to restrict interviews to key issues from the societal perspective. For a valuation of physician contacts, we followed the recommendations from Krauth et al , 14 which allow for only an approximation of costs.
Our cost-effectiveness calculation is based on cost consequences during follow-up and does not include expenses regarding guideline development or the implementation itself, which accounts for 5% of total costs in the intervention arms. Nevertheless, implementation benefi ts are expected to last longer than the study period and to be of use for more patients than our study participants. This makes implementation cost negligible and supports judgment on cost-effectiveness on the basis of follow-up health care utilization only. LBP. 21 However, we think that these baseline costs are a surrogate for patients' health care utilization pattern. Results from sensitivity analysis underline the need not to merely rely on the evaluation of randomization success by reviewing non-cost parameters such as clinical data or sociodemographic characteristics but to include some sort of health care utilization measurement prior to the study period.
International Literature
There are various reasons why the implementation strategies did not prove to be cost-effective after allowing for baseline costs. Recent reviews on the effectiveness of implementation strategies have highlighted the evidence for the effectiveness of multifaceted intervention, interactive education, and clinical reminder systems. 22 Although our interventions comply with this evidence, the intervention may have been too weak. Minor effects or just tendencies as study results are common in primary care intervention studies, referring partly to the complexity of these studies. 23 A systematic review by Grimshaw et al 24 found modest to moderate improvement of care in the majority of studies on GI strategies. Only about a third of the included studies (n = 235) reported economic data with rather poor methodology, which makes it diffi cult to draw conclusions regarding cost-effectiveness. Hoeijenbos et al 25 studied the cost-effectiveness of an active implemen- Figure 2 (change in functional capacity during 6 months comparing guideline implementation versus controls). Solid ellipses indicate raw CEP without adjustment; dotted ellipses, CEP adjusted for cluster effects; dashed ellipses, CEP adjusted for cluster effects and baseline cost differences. The inner and outer ellipses refer to the 5% and 95% confi dence levels, respectively.
tation strategy compared with the standard dissemination strategy of the Dutch physiotherapy guideline. The authors found no differences in the quality of life, direct medical costs, and productivity costs. This was different in a recent study by Lambeek et al 26 who did a secondary cost-effectiveness analysis on a study evaluating the effects of integrated care of patients listed as sick with chronic LBP. The authors found lower total costs in the intervention group compared with controls concluding its cost-effectiveness.
CONCLUSION
Our study shows superiority by trend of the intervention arms with respect to functional capacity, days in pain, and follow-up cost. Furthermore, it underlines the importance of including health care utilization data at baseline when performing economic analyses. Future research is needed to further clarify the cost-effectiveness of different implementation strategies and the cost consequences of evidence-based LBP management.
➢ Key Points
International guidelines have been developed to improve evidence-based care for LBP patients. To fi nd a cost-eff ective implementation strategy seems crucial to give support to decision makers in health care. We present a secondary cost-eff ectiveness study alongside a cluster randomized controlled trial evaluating 2 GI strategies (physician education alone and in combination with MC by practice nurses). At fi rst glance, both intervention groups show lower total costs and better outcomes compared with controls. However, eff ects attenuate when adjusting for clustering of data and health care costs 6 months prior to the study period. Future cost-eff ectiveness studies should include information on health care utilization behavior prior to the study period instead of merely relying on randomization success shown by non-cost parameters such as clinical data and sociodemographic characteristics.
